‌‌‌‌‌‌‌‌‌‌‌

Cynata Therapeutics Limited‌‌‌‌‌‌‌‌‌‌‌‌‌

ACN 104 037 372‌‌

and its controlled entities

Annual report for the financial year ended 30 June 2017‌‌‌

Corporate directory

Board of Directors

Dr Paul Wotton Non-Executive Chairman

Dr Ross Macdonald Managing Director/Chief Executive Officer Dr Stewart Washer Non-Executive Director

Dr John Chiplin Non-Executive Director

Mr Peter Webse Non-Executive Director

Company Secretary

Mr Peter Webse

Registered and Principal Office

Level 3, 62 Lygon Street

Carlton, Victoria 3053

Tel: +61 3 9824 5254

Fax: +61 3 9822 7735

Email: admin@cynata.com

Postal Address

PO Box 7165

Hawthorn North, Victoria 3122

Website

Website: www.cynata.com

Auditors

Stantons International Level 2, 1 Walker Avenue‌‌

West Perth, Western Australia 6005

Share Registry

Automic Registry Services Level 2, 267 St Georges Terrace Perth, Western Australia 6000 Tel: +61 8 9324 2099

Fax: +61 8 9321 2337

Stock Exchange

Australian Securities Exchange Level 40, Central Park

152-158 St Georges Terrace Perth, Western Australia 6000

ASX Code

CYP

Annual report for the financial year ended 30 June 2017

Contents

Directors' report………………………………………………………………………………………………………

1

Operating and financial review………………………………………………………………………………..

6

Remuneration report……………………………………………………………………………………………….

10

Auditor's independence declaration………………………………………………………………………..

17

Independent auditor's report………………………………………………………………………………….

18

Directors' declaration……………………………………………………………………………………………..

22

Consolidated statement of profit or loss and other comprehensive income………..…

23

Consolidated statement of financial position………………………………………………….………

24

Consolidated statement of changes in equity…………………………………………………………

25

Consolidated statement of cash flows…………………………………………………………….………

26

Notes to the consolidated financial statements.…………………………………………….….……

27

Corporate governance statement…………………………………………………………………………..

52

Additional securities exchange information…………………………………………………………….

59

Directors' report

The directors of Cynata Therapeutics Limited ("Cynata" or "the Company") and its controlled entities ("the Group") submit herewith the annual report of the Group for the financial year ended 30 June 2017. In order to comply with the provisions of the Corporations Act 2001, the directors report as follows:

Information about the directors

The names and particulars of the directors of the Group during or since the end of the financial year are:

Name

Particulars

Dr Paul Wotton

MBA, PhD

Chairman, joined the Board in June 2016 as Non-Executive Director and

appointed as Chairman on 28 February 2017. Dr Wotton is currently the President and CEO of Sigilon Inc. and was previously President and CEO of Ocata Therapeutics Inc. (NASDAQ: OCAT) taking the company through a take-over by Atellas Pharma Inc., in a US$379 million all cash transaction. Prior to Ocata, Dr Wotton had served as President and CEO of Antares Pharma Inc. (NASDAQ: ATRS), since October 2008. Prior to joining Antares, Dr Wotton was the CEO of Topigen Pharmaceuticals and prior to Topigen, he was the Global Head of Business Development of SkyePharma PLC. Dr Wotton has held senior level positions at Eurand International BV, Penwest Pharmaceuticals, Abbott Laboratories and Merck, Sharp and Dohme. Dr Wotton is a member of the board of Vericel Corporation, a US company developing autologous cellular therapies, a member of the board at Veloxis Pharmaceuticals A/S where he is Chairman of the Compensation Committee and also past Chairman of the Emerging Companies Advisory Board of BIOTEC Canada. Dr Wotton received his PhD in pharmaceutical sciences from the University of Nottingham and an MBA from Kingston Business School. In 2014, he was named New Jersey EY Entrepreneur of the Year in Life Sciences.

Dr Ross Macdonald PhD (Biochemistry), Grad Dip in Bus Admin

Chief Executive Officer, joined the Board in August 2013. Dr Macdonald has over 30 years' experience and a track record of success in pharmaceutical and biotechnology businesses. His career history includes positions as Vice President of Business Development for Sinclair Pharmaceuticals Ltd (now Sinclair IS Pharma), a UK-based specialty pharmaceuticals company and Vice President, Corporate Development for Stiefel Laboratories Inc, the largest independent dermatology company in the world and acquired by GlaxoSmithKline in 2009 for £2.25b. Dr Macdonald has also served as CEO of Living Cell Technologies Ltd, Vice President of Business Development of Connetics Corporation and Vice President of Research and Development of F H Faulding & Co Ltd. Dr Macdonald currently serves as a member of the Investment Committee of UniSeed Management Pty Ltd.

Dr John Chiplin BPharm, PhD, MRPharmS

Non-Executive Director, joined the Board in November 2014. Dr. Chiplin is Managing Director, Newstar Ventures Ltd and has significant international experience in the life science and technology industries. Recent transactions that Dr. Chiplin has been instrumental in include US stemcell company Medistem (acquired by Intrexon), Arana Therapeutics (acquired by Cephalon) and Domantis (acquired by GSK).

- 1 -

Cynata Therapeutics Ltd. published this content on 09 October 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 09 October 2017 06:24:08 UTC.

Original documenthttp://cynata.com/wp-content/uploads/2017/10/17.10.09.Annual-Report-to-Shareholders-1.pdf

Public permalinkhttp://www.publicnow.com/view/5DCF6912A0097B96B174C60C8F9A7DC1F3ABC8E3